Initial adoption of clinical pathways grew from payers mandating their use with individual providers, but there is now greater interest from accountable care organizations and others to use pathways to reduce variation and cost while improving outcomes, explained Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council.
Initial adoption of clinical pathways grew from payers mandating their use with individual providers, but there is now greater interest from accountable care organizations and others to use pathways to reduce variation and cost while improving outcomes, explained Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council.
Transcript (slightly modified)
How are pathways expanding into different healthcare delivery systems, such as accountable care organizations and integrated delivery networks?
When we began this work, we were quite aware of interest in oncology and quite aware of payers working with individual providers to say, “Ok, these are the pathways that we would mutually want to use.”
What we’re also finding is that there is interest beyond the payer being the group that says “These pathways would be good.” As physicians and physician groups and integrated delivery systems take on risk for managing patients over a longitudinal aspect of care, we’re finding greater interested by accountable care organizations, by these integrated delivery systems, to incorporate clinical pathways into what they do and how they do it. Not because it’s mandated by the payer, but because they, too, want to bring some of the same principles of reducing variation, improving patient outcomes, and reducing costs, just like the payers had.
So we’re going to see an evolution, over time, of much more broader pathways adoption.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Science at AACR Aims to Overcome Cancer Care Barriers
April 24th 2025A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.
Read More